EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Differential expression of forkhead box protein A1 and androgen receptor in prostate cancer: biomarkers of aggressiveness and targeted therapy

Essam E. Ayad, Heba Khalil, Eman G. El-Gammal, Amira Kamel, Abeer M. A. Mohammed

Egyptian Journal of Pathology · 2026-01 · 46 (1) · 44-52

DOI: 10.4103/egjp.egjp_22_25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Egyptian Journal of Pathology, online erschienen am 21.07.2026. Verfasst von Essam E. Ayad und 4 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To analyze the immunohistochemical expression of androgen receptor (AR) and forkhead box protein A1 (FOXA1) in prostate carcinoma, and to evaluate the correlation between their expression levels and various clinical and pathological parameters, to determine their potential prognostic significance and explore their viability as therapeutic targets. Patients and methods A total of 50 cases of prostatic carcinoma, 25 cases of Trans-Rectal Ultrasound-Guided Core biopsies, 24 cases of radical prostatectomy specimens, and only one case of Transurethral Resection of the Prostate biopsy were collected. Samples were immunohistochemically analyzed for AR and FOXA1 expression and correlated with clinicopathologic variables.

Results

FOXA1 and AR expressions dividing the studied prostatic adenocarcinoma cases into; low FOXA1 expression group; eight (16%) cases and six (12%) cases, respectively, and high FOXA1 expression group; 42 (84%) cases and 44 (88%) cases, respectively. FOXA1 expression was statistically correlated with the tumor extent, the Gleason Score, and the Gleason Grade group ( P =0.018, 0.008, and 0.012, respectively). On the other hand, no significant association was found between AR expression and the tumor extent, the Gleason Score, as well as the Gleason Grade group ( P =0.119, 0.829, and 0.819, respectively). Although more than 86% of the cases with high AR expression highly expressed FOXA1, the expression of both FOXA1 and AR in prostatic adenocarcinoma was not significantly correlated ( P =0.242).

Conclusion

Our findings suggest a significant role for both AR and FOXA1 in prostatic carcinogenesis. Notably, FOXA1 expression in prostate cancer appears to be a robust predictor of tumor aggressiveness and poor prognosis. Rather than being a prognostic factor, AR might be considered a ‘default‘ oncogenic driver of prostate tumorigenesis.

Zitieren

APA

Ayad, E. E., Khalil, H., El-Gammal, E. G., Kamel, A., & Mohammed, A. M. A. (2026). Differential expression of forkhead box protein A1 and androgen receptor in prostate cancer: biomarkers of aggressiveness and targeted therapy. Egyptian Journal of Pathology, 46(1), 44-52. https://doi.org/10.4103/egjp.egjp_22_25

Vancouver

Ayad EE, Khalil H, El-Gammal EG, Kamel A, Mohammed AMA. Differential expression of forkhead box protein A1 and androgen receptor in prostate cancer: biomarkers of aggressiveness and targeted therapy. Egyptian Journal of Pathology. 2026;46(1):44-52. doi:10.4103/egjp.egjp_22_25

BibTeX
@article{Ayad2026,
  author = {Ayad, Essam E. and Khalil, Heba and El-Gammal, Eman G. and Kamel, Amira and Mohammed, Abeer M. A.},
  title = {Differential expression of forkhead box protein A1 and androgen receptor in prostate cancer: biomarkers of aggressiveness and targeted therapy},
  journal = {Egyptian Journal of Pathology},
  year = {2026},
  volume = {46},
  number = {1},
  pages = {44--52},
  doi = {10.4103/egjp.egjp_22_25}
}
Kostenlos starten →